ACP- 2591 is highlighted on slide 91 of the Acadia R&D day presentation as a "next generation investigational approaches to Rett Syndrome" and includes the following statements: *In relation to Rett Syndrome NNZ-2591 apparently indicates "better brain penetrance" which seems to mean in English better than Daybue: "Brain penetrance refers to the ability of a drug or other substance to cross the blood-brain barrier (BBB) and reach the brain in therapeutically relevant concentrations. The BBB is a highly selective barrier that protects the brain from harmful substances while allowing essential nutrients and other molecules to pass through. Achieving adequate brain penetrance is crucial for the effectiveness of drugs targeting the central nervous system (CNS), such as those used for treating brain tumors or neurodegenerative diseases" *Undisclosed Activities [The lack of clear English here [and this is just my view] is that Acadia simply do not wish to destroy the current Daybue market by announcing that a better product is not far off]. Kens
NEU Price at posting:
$14.20 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)